WO2011005714A3 - Compositions liposomales de bendamustine - Google Patents

Compositions liposomales de bendamustine Download PDF

Info

Publication number
WO2011005714A3
WO2011005714A3 PCT/US2010/040990 US2010040990W WO2011005714A3 WO 2011005714 A3 WO2011005714 A3 WO 2011005714A3 US 2010040990 W US2010040990 W US 2010040990W WO 2011005714 A3 WO2011005714 A3 WO 2011005714A3
Authority
WO
WIPO (PCT)
Prior art keywords
bendamustine
liposomal compositions
compositions
treating
lymphoproliferative disorders
Prior art date
Application number
PCT/US2010/040990
Other languages
English (en)
Other versions
WO2011005714A2 (fr
Inventor
Alan Saven
Darren Sigal
Original Assignee
Alan Saven
Darren Sigal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alan Saven, Darren Sigal filed Critical Alan Saven
Publication of WO2011005714A2 publication Critical patent/WO2011005714A2/fr
Publication of WO2011005714A3 publication Critical patent/WO2011005714A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

L'invention porte sur des compositions comprenant un liposome couplé à un ligan de siglec comprenant de la bendamustine, et sur leur utilisation dans le traitement de troubles lymphoprolifératifs des lymphocytes B et sur des compositions comprenant des liposomes non ciblés comprenant de la bendamustine, et sur leur utilisation dans le traitement de troubles lymphoprolifératifs des lymphocytes B et de tumeurs solides.
PCT/US2010/040990 2009-07-07 2010-07-02 Compositions liposomales de bendamustine WO2011005714A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27033009P 2009-07-07 2009-07-07
US61/270,330 2009-07-07
US23890709P 2009-09-01 2009-09-01
US61/238,907 2009-09-01

Publications (2)

Publication Number Publication Date
WO2011005714A2 WO2011005714A2 (fr) 2011-01-13
WO2011005714A3 true WO2011005714A3 (fr) 2011-05-26

Family

ID=43429800

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/040990 WO2011005714A2 (fr) 2009-07-07 2010-07-02 Compositions liposomales de bendamustine

Country Status (1)

Country Link
WO (1) WO2011005714A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1655038A1 (fr) * 2003-08-01 2006-05-10 National Institute of Advanced Industrial Science and Technology Liposome dirige sur une cible, enterique et a absorption commandee possedant une chaine de sucre, ainsi que remede contre le cancer contenant ce liposome et diagnostic mettant en oeuvre ce liposome
US20060193906A1 (en) * 2002-01-30 2006-08-31 National Institute Of Advanced Industrial Science And Technology Sugar-modified liposome and products comprising the liposome
US20070286896A1 (en) * 2003-08-01 2007-12-13 National Institute Of Advanced Industrial Science And Technology Therapeutic or Diagnostic Drug for Inflammatory Disease Comprising Targeting Liposome
US20080193511A1 (en) * 2004-12-23 2008-08-14 Ulrich Massing Manufacture of Lipid-Based Nanoparticles Using a Dual Asymmetric Centrifuge

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060193906A1 (en) * 2002-01-30 2006-08-31 National Institute Of Advanced Industrial Science And Technology Sugar-modified liposome and products comprising the liposome
EP1655038A1 (fr) * 2003-08-01 2006-05-10 National Institute of Advanced Industrial Science and Technology Liposome dirige sur une cible, enterique et a absorption commandee possedant une chaine de sucre, ainsi que remede contre le cancer contenant ce liposome et diagnostic mettant en oeuvre ce liposome
US20070286896A1 (en) * 2003-08-01 2007-12-13 National Institute Of Advanced Industrial Science And Technology Therapeutic or Diagnostic Drug for Inflammatory Disease Comprising Targeting Liposome
US20080193511A1 (en) * 2004-12-23 2008-08-14 Ulrich Massing Manufacture of Lipid-Based Nanoparticles Using a Dual Asymmetric Centrifuge

Also Published As

Publication number Publication date
WO2011005714A2 (fr) 2011-01-13

Similar Documents

Publication Publication Date Title
EP2618817A4 (fr) Composés de liposomes ciblants et utilisations associées
EP2252247A4 (fr) Pansement résistant au déchirement, utilisable dans le traitement des plaies par pression négative
ZA201209145B (en) Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application
ZA201300685B (en) Anticancer derivatives,preparation thereof and therapeutic use thereof
WO2010027798A3 (fr) Dispositifs d’ablation et procédés associés
EP2124550A4 (fr) Oxabicycloheptanes et oxabicycloheptènes, leur préparation et leur utilisation
EP2246056A4 (fr) Agent d'amélioration d'un effet antitumoral comprenant une préparation d'oxaliplatine liposome, et agent antitumoral comprenant la préparation de liposome
EP2307344A4 (fr) Oxabicycloheptanes et oxabicycloheptènes, préparation et utilisation associées
IL213920A0 (en) 3,3'-spiroindolinone derivatives as anticancer agents
ZA201004086B (en) Rasagiline formulations, their preparation and use
IL215059A (en) Liposome preparation that includes an arboline and a process for its preparation
IL216238A0 (en) 7-aza-spiro[3.5]nonane-7-carboxylate derivatives, preparation thereof, and therapeutic use thereof
HK1159108A1 (en) Pyridino-pyridinone derivatives, preparation thereof, and therapeutic use thereof
EP2601907A4 (fr) Outil de soin contenant un médicament
AP2729A (en) Dividable galenical form allowing modified releaseof the active ingredient
HK1151488A1 (en) Game system, jack-pot lot device constituting the game system, and game machine
IL209602A0 (en) Amphiphilic branched polymers and their use as emulsifiers
IL219888A0 (en) Pyridine-pyridinone derivatives, preparation and therapeutic use thereof
EP2538523A4 (fr) Rotor et machine dynamoélectrique utilisant le rotor
EP2241382A4 (fr) Laminoir et laminoir en tandem comportant celui-ci
ZA201300183B (en) " backing having three -layer structure and aqueous patch using the backing "
PL2252403T3 (pl) Młyn krążnikowy
EP2269612A4 (fr) Préparation de gouttes ophtalmiques et utilisation
HK1148937A1 (en) Improved liposomes and uses thereof
WO2011005714A3 (fr) Compositions liposomales de bendamustine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10797689

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10797689

Country of ref document: EP

Kind code of ref document: A2